Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)
Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-015-1175-3
Published Online: 2015-03-25
Published Print: 2015-12
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy
Suenaga, Mitsukuni
Nishina, Tomohiro
Mizunuma, Nobuyuki
Yasui, Hisateru
Ura, Takashi
Denda, Tadamichi
Ikeda, Junichi
Esaki, Taito
Nishisaki, Hogara
Takano, Yoshinao
Sugiyama, Yasuyuki
Muro, Kei
License valid from 2015-03-25